** Shares of gene therapy developer Sarepta Therapeutics SRPT.O up 2.1% to $63.21
** H.C. Wainwright raises SRPT's rating to "neutral" from "sell"
** Still expect Elevidys revenue to fall short in 2H25 — more so now after the recently reported patient death — expect a continued bolus demand effect from the June 2024 approval in older and non-ambulatory groups, brokerage says
** SRPT last month said a 16-year-old boy died from acute liver failure months after receiving U.S.-approved gene therapy Elevidys, for a rare muscular dystrophy
** Wainwright also believes there is a chance that the 2025 Elevidys ramp may sour faster—perhaps as soon as 2Q25— given the likelihood of increased hesitance by prescribers/patients
** The departure of U.S. FDA's top vaccine official, Peter Marks, casts uncertainty on the future of SRPT's development-stage portfolio - brokerage
** Up to last close, stock had fallen 49% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。